TAE Life Sciences (TLS) has signed a letter of intent with the OSUCCC – James to develop boron-based drug compounds for ...

China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723) ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from ...

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.